

Portola Pharmaceuticals Inc (PTLA) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/P886A027BBCEN.html>

Date: July 2020

Pages: 47

Price: US\$ 125.00 (Single User License)

ID: P886A027BBCEN

Abstracts

Portola Pharmaceuticals Inc (PTLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Portola Pharmaceuticals Inc (Portola Pharmaceuticals) is a biopharmaceutical company that discovers, and develops therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. The company's products portfolio include Betrixaban, an oral once-daily Factor Xa inhibitor anticoagulant that inhibits the activity of Factor Xa; andexanet alfa, a recombinant protein designed to reverse anticoagulant activity of both direct and indirect Factor Xa inhibitors; and cerdulatinib, an oral, dual Syk-JAK inhibitor in development to treat hematologic cancers. Portola Pharmaceuticals provides compounds using biomarker and genetic approaches for clinical, regulatory and commercial purpose of life-saving therapies. The company works in collaboration with other pharmaceutical and biotechnology companies for the clinical development of its lead candidates. Portola Pharmaceuticals is headquartered in South San Francisco, California, the US.

Portola Pharmaceuticals Inc Key Recent Developments

May 06,2020: Alexion to buy Portola Pharmaceuticals for \$1.41bn

Mar 18,2020: Portola Pharmaceuticals announces proactive steps supporting public health efforts to combat coronavirus (COVID-19)

Feb 26,2020: Portola Pharmaceuticals reports fourth quarter and full-year 2019 financial results and provides corporate update

Feb 03,2020: Portola Pharmaceuticals appoints Rajiv Patni, M.D., as Executive Vice President and Chief Medical Officer

Jan 09,2020: Portola announces preliminary full year 2019 Andexxa Global net revenues of approximately \$111 million

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the

revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Portola Pharmaceuticals Inc - Key Facts
Portola Pharmaceuticals Inc - Key Employees
Portola Pharmaceuticals Inc - Key Employee Biographies
Portola Pharmaceuticals Inc - Major Products and Services
Portola Pharmaceuticals Inc - History
Portola Pharmaceuticals Inc - Company Statement
Portola Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Portola Pharmaceuticals Inc - Business Description
R&D Overview
Portola Pharmaceuticals Inc - Corporate Strategy
Portola Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Portola Pharmaceuticals Inc - Strengths
Portola Pharmaceuticals Inc - Weaknesses
Portola Pharmaceuticals Inc - Opportunities
Portola Pharmaceuticals Inc - Threats
Portola Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCENCES FINANCIAL DEALS AND ALLIANCES

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020

Portola Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 06, 2020: Alexion to buy Portola Pharmaceuticals for \$1.41bn

Mar 18, 2020: Portola Pharmaceuticals announces proactive steps supporting public health efforts to combat coronavirus (COVID-19)

Feb 26, 2020: Portola Pharmaceuticals reports fourth quarter and full-year 2019 financial results and provides corporate update

Feb 03, 2020: Portola Pharmaceuticals appoints Rajiv Patni, M.D., as Executive Vice President and Chief Medical Officer

Jan 09, 2020: Portola announces preliminary full year 2019 Andexxa Global net revenues of approximately \$111 million

Dec 23, 2019: Portola Pharmaceuticals to webcast corporate update on January 14, 2020

Dec 17, 2019: Portola Pharmaceuticals to support new American Heart Association initiative to address hemorrhagic stroke

Nov 05, 2019: Portola Pharmaceuticals reports third quarter 2019 financial results and provides corporate update

Sep 19, 2019: Portola Pharmaceuticals appoints Ted W. Love, M.D., to its Board of Directors

Aug 07, 2019: Portola Pharmaceuticals reports second quarter 2019 financial results and provides corporate update

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Portola Pharmaceuticals Inc, Key Facts
Portola Pharmaceuticals Inc, Key Employees
Portola Pharmaceuticals Inc, Key Employee Biographies
Portola Pharmaceuticals Inc, Major Products and Services
Portola Pharmaceuticals Inc, History
Portola Pharmaceuticals Inc, Subsidiaries
Portola Pharmaceuticals Inc, Key Competitors
Portola Pharmaceuticals Inc, Ratios based on current share price
Portola Pharmaceuticals Inc, Annual Ratios
Portola Pharmaceuticals Inc, Annual Ratios (Cont...1)
Portola Pharmaceuticals Inc, Interim Ratios
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Portola Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Portola Pharmaceuticals Inc, Performance Chart (2015 - 2019)

Portola Pharmaceuticals Inc, Ratio Charts

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Xencor Inc

SELLAS Life Sciences Group Inc

KemPharm Inc

Inotek Pharmaceuticals Corp

I would like to order

Product name: Portola Pharmaceuticals Inc (PTLA) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/P886A027BBCEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P886A027BBCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970